Asteri Pharma Expands Partnership with Esteve to Strengthen Rare Disease Portfolio in ANZ

Asteri Pharma Pty Ltd (Asteri Pharma) is pleased to announce the expansion of our strategic partnership with Esteve, becoming the exclusive licensing partner for two additional therapies within Esteve’s Endocrinology and Oncology portfolio.

This expanded portfolio introduces innovative therapies that play a vital role in the management of rare endocrinology and neuroendocrinology conditions, including Cushing’s syndrome and other complex disorders. These additions seamlessly complement our existing rare disease offerings and further strengthen Asteri Pharma’s commitment to delivering impactful solutions for patients with significant unmet medical needs.

Under this enhanced agreement, Asteri Pharma will oversee full end-to-end commercialisation across Australia and New Zealand ensuring timely and effective access to these important therapies.

This collaboration represents a significant step forward in our commitment to improving access to treatments for patients living with rare and complex conditions.   

 “Partnership is at the heart of what we do. We are proud to collaborate with international companies like ESTEVE who share our vision to provide ongoing access to innovative therapies, for people who rely on them.” Benet Irish, Chief Executive Officer (CEO), ASTERI Pharma.

For further information, please contact Benet Irish, CEO, ASTERI Pharma

birish@asteripharma.com   

Phone: 1800 178 402 (AUS)

About ASTERI PHARMA

Asteri Pharma is an Australian-based biopharmaceutical company delivering innovative licensing and distribution solutions to unlock the value of new and emerging medicines for the Australian, ANZ and APAC markets.

We’re driven by purpose—access for all, integrity in action, and the ambition to reach beyond limits. Our focus is on addressing diseases with high unmet need, closing the equity gap, and ensuring patients get faster access to life-changing treatments.

About ESTEVE

To obtain more information about ESTEVE, visit www.esteve.com.